Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process
- 1 September 1996
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 40 (9) , 2126-2130
- https://doi.org/10.1128/aac.40.9.2126
Abstract
The aim of this work was to examine the mechanism involved in intestinal elimination of the two optical isomers of ofloxacin in the rat. An intestinal segment was isolated in situ and perfused with saline, while drug solution was administered via the carotid artery. Blood samples and intestinal effluents were collected and analyzed by a high-performance liquid chromatography method. We observed saturable and stereoselective intestinal elimination of the ofloxacin enantiomers. The elimination process favored the R-(+) form of the molecule. After a parenteral dose of 20 mg of racemic ofloxacin per kg of body weight, intestinal clearances were 0.23 +/- 0.03 versus 0.30 +/- 0.03 ml/min for S-(-)- and R-(+)-ofloxacin, respectively. Ciprofloxacin and pefloxacin interfered with ofloxacin elimination and significantly reduced the intestinal clearance of S-(-)- and R-(+)-ofloxacin. With concomitant ciprofloxacin, intestinal clearances became 0.13 +/- 0.02 versus 0.17 +/- 0.03 ml/min and 0.14 +/- 0.01 versus 0.19 +/- 0.05 ml/min with pefloxacin for S-(-)- and R-(+)-ofloxacin, respectively. Those findings argue for the presence of a common transport system in the rat intestine with variable affinities for fluoroquinolones. In addition, verapamil and quinidine, two P-glycoprotein blockers, significantly reduced the intestinal elimination of both ofloxacin isomers (with concomitant verapamil, intestinal clearances were 0.12 +/- 0.02 versus 0.18 +/- 0.03 ml/min for S-(-)- and R-(+)-ofloxacin, respectively, while with concomitant quinidine, values were 0.18 +/- 0.01 versus 0.23 +/- 0.01 ml/min without modifying their areas under the concentration-time curve in serum. Similar results were found with another fluoroquinolone, ciprofloxacin, in previous work. P-glycoprotein appears to be involved in the intestinal elimination of fluoroquinolones in rats. The characterization of fluoroquinolone intestinal elimination has significant clinical relevance for the better evaluation of the influence of this secretory pathway on antibiotic efficacy and selection of resistant bacteria within the intestinal flora.Keywords
This publication has 31 references indexed in Scilit:
- Pefloxacin Clinical PharmacokineticsClinical Pharmacokinetics, 1994
- The Stimulative Effect of Diffusion Potential on Enoxacin Uptake across Rat Intestinal Brush-border MembranesJournal of Pharmacy and Pharmacology, 1994
- Lomefloxacin Clinical PharmacokineticsClinical Pharmacokinetics, 1993
- Effect of Antacid Medication on the Pharmacokinetics of TemafloxacinClinical Pharmacokinetics, 1992
- Male-to-female transmission of human immunodeficiency virus infection by oro-genital sexEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- Efflux of bis-carboxyethyl-carboxyfluorescein (BCECF) by a novel ATP-dependent transport mechanism in epithelial cellsBiochemical and Biophysical Research Communications, 1990
- In vitro Antibacterial Activity of DR-3355, the S-(––)-Isomer of OfloxacinChemotherapy, 1990
- Stereoselective Metabolic Disposition of Enantiomers of Ofloxacin in RatsXenobiotica, 1989
- Comparative Pharmacokinetics of New QuinolonesDrugs, 1987
- Clinical uses of nalidixic acid analogues: the fluoroquinolonesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986